Immune check point inhibitors are associated with a spectrum of cardiac events in patients with cancer
- 21 February 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (16), 1636
- https://doi.org/10.1093/eurheartj/ehab066
Abstract
This commentary refers to the article ‘The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study’, by M. D’Souza et al., doi:10.1093/eurheartj/ehaa884 and the discussion piece ‘Cardiac events associated with ICI therapy—the devil is in the detail’, by M.S. Anker et al., doi:10.1093/eurheartj/ehab063.This publication has 5 references indexed in Scilit:
- The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish studyEuropean Heart Journal, 2020
- Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective studyEuropean Journal of Heart Failure, 2020
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance studyThe Lancet Oncology, 2018
- Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: A U.S. Food and Drug Administration pooled analysis.Journal of Clinical Oncology, 2018
- Cardiac Toxicity of Immune Checkpoint InhibitorsCirculation, 2017